Overview

A Study of LY573636-sodium in Patients With Metastatic Breast Cancer

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636-sodium for metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company